Journal
ADDICTION
Volume 114, Issue 1, Pages 150-166Publisher
WILEY
DOI: 10.1111/add.14393
Keywords
Estimates; HCV; IDU; injecting drug use; PWID; viraemic
Categories
Funding
- Australian National Drug and Alcohol Research Centre, UNSW Sydney
- Open Society Foundation
- World Health Organization
- Global Fund
- UNAIDS
- John C Martin Foundation
- Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowships
- NHMRC Career Development Fellowship
- NHMRC Early Career Fellowship
- Bill & Melinda Gates Foundation
- Australian Government Department of Health and Ageing
- NHMRC Practitioner Fellowship
- PhD scholarship from the Engineering and Physical Sciences Research Council (EPSRC)
- Canadian Network on Hepatitis C (CanHepC)
- National Institute for Health Research (NIHR)
- NIHR Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol
- NIHR HPRU in Blood-Borne and Sexually Transmitted Infections at University College London
- National Institute for Drug Abuse [R01 DA037773-01A1]
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA044170, R01DA037773] Funding Source: NIH RePORTER
- MRC [MR/K006525/1] Funding Source: UKRI
Ask authors/readers for more resources
Background and Aims People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country-levels. Methods Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV. Results There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0-2.1), eastern Europe (1.5 million, UI = 0.7-2.4) and North America (1.0 million, UI = 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7-56.7), Latin America (22.0%, UI = 15.3-30.4) and eastern Europe (17.9%, UI = 8.2-30.9). Conclusions Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available